文献速递腹部MR

基于扩散加权MRI虚拟弹性成像对慢性乙型肝炎相关肝纤维化分期:与血清纤维化指标的对比

Staging Chronic Hepatitis B Related Liver Fibrosis with Diffusion-weighted MRI-based Virtual Elastography: Comparisons with Serum Fibrosis Indexes.
PubMed 文献 · Clin Radiol · 2024-11-16

回顾性纳入145例慢性乙型肝炎患者,用b值200和1500/mm²的DWI衍生虚拟剪切模量μDiff,并与APRI、FIB-4、S指数、Fibro Q、GPR比较肝纤维化分期效能。μDiff诊断显著纤维化、进展期纤维化、肝硬化的AUC分别为0.725、0.817、0.764;对进展期纤维化,μDiff的AUC高于FIB-4(0.686)和Fibro Q(0.638)(P<0.05);μDiff联合各血清指标对进展期纤维化和肝硬化的AUC均显著高于单一血清指标(均P<0.05)。

要点

  • μDiff诊断进展期纤维化AUC 0.817,高于FIB-4的0.686和Fibro Q的0.638(P<0.05)。
  • μDiff联合各血清指标对进展期纤维化和肝硬化的AUC均显著高于单一血清指标(均P<0.05)。
  • μDiff、APRI、FIB-4、S指数、Fibro Q、GPR随肝纤维化进展而升高(r=0.23-0.52,P<0.05)。

核心结论

  • 基于DWI的虚拟MR弹性成像可评估慢性乙型肝炎患者的肝纤维化分期,对进展期纤维化的诊断效能优于FIB-4和Fibro Q;μDiff与各血清指标联合对进展期纤维化和肝硬化的诊断效能似乎优于单一血清指标。

研究设计与样本

  • 回顾性研究,纳入145例慢性乙型肝炎患者;虚拟剪切模量μDiff由b值200和1500/mm²的DWI采集衍生;计算APRI、FIB-4、S指数、Fibro Q和GPR;比较μDiff与血清指标对肝纤维化分期的诊断效能。

诊断标准与关键数值

  • μDiff诊断显著纤维化的AUC为0.725。
  • μDiff诊断进展期纤维化的AUC为0.817。
  • μDiff诊断肝硬化的AUC为0.764。
  • μDiff联合APRI、FIB-4、S指数、Fibro Q、GPR诊断显著纤维化的AUC分别为0.779、0.772、0.763、0.728、0.756。
  • μDiff联合APRI、FIB-4、S指数、Fibro Q、GPR诊断进展期纤维化的AUC分别为0.856、0.842、0.834、0.831、0.834。

临床应用与阅片要点

  • 对进展期纤维化,μDiff的AUC高于FIB-4(0.686)和Fibro Q(0.638)(P<0.05)。
  • μDiff联合各血清指标对进展期纤维化和肝硬化的AUC均显著高于单一血清指标(均P<0.05)。
  • μDiff、APRI、FIB-4、S指数、Fibro Q、GPR随肝纤维化进展而升高(r=0.23-0.52,P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate and compare the diagnostic performance of diffusion-weighted imaging (DWI)-based virtual magnetic resonance (MR) elastography and serum fibrosis indexes for staging liver fibrosis in patients with chronic hepatitis B (CHB).

MATERIALS AND METHODS: This retrospective study included 145 patients with CHB. Virtual shear modulus (μDiff) was derived from DWI acquisition with b values of 200 and 1500/mm2. Aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 index (FIB-4), S index, Fibro Q and gamma-glutamyl transpeptidase to platelet ratio (GPR) were calculated. The diagnostic efficacies of μDiff and serum indexes for staging liver fibrosis were compared.

RESULTS: μDiff, APRI, FIB-4, S index, Fibro Q, and GPR increased as the hepatic fibrosis progressed (r=0.23-0.52, P<0.05). Areas under the curves (AUCs) of μDiff were 0.725, 0.817 and 0.764 for significant fibrosis, advanced fibrosis, and cirrhosis, respectively. μDiff had greater AUC over FIB-4 (0.686) and Fibro Q (0.638) for advanced fibrosis (P<0.05). The AUCs of combination of μDiff with APRI, FIB-4, S index, Fibro Q, and GPR individually were 0.779, 0.772, 0.763, 0.728, and 0.756 for significant fibrosis, 0.856, 0.842, 0.834, 0.831, and 0.834 for advanced fibrosis, 0.811, 0.818, 0.784, 0.835, and 0.788 for cirrhosis, respectively. The AUCs of the combinations were significantly higher than individual serum index for advanced fibrosis and cirrhosis (all P<0.05).

CONCLUSION: DWI-based virtual MR elastography could estimate liver fibrosis stages in patients with CHB, which outperformed FIB-4 and Fibro Q for advanced fibrosis. The combination of μDiff with each serum index appears superior to individual serum index for advanced fibrosis and cirrhosis.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Yang L, Zhou G, Liu L, et al. Staging Chronic Hepatitis B Related Liver Fibrosis with Diffusion-weighted MRI-based Virtual Elastography: Comparisons with Serum Fibrosis Indexes. Clin Radiol. 2024. PMID: 39657563. doi:10.1016/j.crad.2024.106750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。